An observational study in Autosomal Dominant Optic Atrophy, Optic Atrophy, Autosomal Dominant and Optic Atrophies, Hereditary, sponsored by PYC Therapeutics. Terminated at 7 sites in 6 countries. Open to participants aged 8 Years and older. Per ClinicalTrials.gov, last updated 2025-03-14.
Sponsored by PYC Therapeutics · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to characterize the disease progression of confirmed OPA1 mutation-associated autosomal dominant optic atrophy (ADOA) by evaluating the changes in ocular structural and functional outcomes.
This is a multi-center, longitudinal, prospective, observational natural history study of patients with confirmed OPA1 mutation (haploinsufficiency) associated ADOA. The study will be conducted at up to 10 sites across the United States, Australia and Europe.
Each participant's medical record will be reviewed for historical information, and clinical data will be recorded in a secure database. Natural history data will be collected prospectively and will include ophthalmic exams, imaging studies and electrophysiological testing. Assessments will be conducted as described in this protocol approximately every 3 months in the first year and every 6 months in the second year of the study after each participant's baseline visit
PYC Therapeutics is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population will consist of approximately 40 participants (80 eyes) with a genetically confirmed OPA1 mutation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For sites performing the Detection of apoptosis in retinal cells (DARC) procedure, and in volunteers ≥ 12 years only:
Female volunteers must:
I. Be of non- at least 6 weeks before the screening visit or (where postmenopausal is defined as no menses for 12 months without an alternative medical cause), or
II. If of childbearing potential, must:
Male volunteers must:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Best-corrected High Contrast Visual Acuity (HCVA)
Best-corrected high contrast visual acuity (HCVA) for both distance and near will be evaluated using the ETDRS electronic visual acuity charts and the MNRead acuity chart
Time frame: Baseline through Year 2
Low Contrast Visual Acuity (LCVA)
Low contrast visual acuity (LCVA) for both distance and near will be evaluated using the low contrast ETDRS letter chart
Time frame: Screening through Year 2
Contrast Sensitivity
Contrast sensitivity recorded using the Pelli-Robson chart
Time frame: Baseline through Year 2
Color Vision
Color vision tested using the Hardy Rand Rittler test
Time frame: Baseline through Year 2
Retinal Thickness
Change retinal thickness is measured using spectral domain optical coherence tomography (SD-OCT), as measured by the central reading center (SD-OCT), as measured by the central reading center
Time frame: Baseline through Year 2
Ellipsoid Zone (EZ) Volume
Change in EZ volume measured using spectral domain optical coherence tomography (SD-OCT), as measured by the central reading center
Time frame: Baseline through Year 2
Ellipsoid Zone (EZ) Area
Change in EZ area measured using spectral domain optical coherence tomography (SD-OCT), as measured by the central reading center
Time frame: Baseline through Year 2
Visual Field Sensitivity
Visual field sensitivity measured by automated static perimetry
Time frame: Baseline through Year 2
Multifocal Visual Evoked Potential (mfVEP)
The waveform of the evoked responses, the latency, and amplitude are analyzed.
Time frame: Baseline through Year 2
Pregnancy Test
A urine human chorionic gonadotropin (hCG) pregnancy conducted in all women of childbearing potential (WOCBP) \> 12 years of age at baseline. If a urine test is positive, the DARC procedure will not be performed.
Time frame: Baseline
DARC (Detection of Apoptosing Retinal Cells)
The DARC test is conducted using an IV injection of fluorescently labelled Annexin V (called ANX776). Individual stressed and apoptotic retinal cells are visible as white spots on the image for DARC count, which are quantified using a confocal scanning laser ophthalmoscope using the indocyanine green angiography (ICGA) settings.
Time frame: Baseline through Year 2
Flavoprotein Fluorescence (FPF)
Functional imaging of mitochondria using Flavoprotein Fluorescence.
Time frame: Baseline through Year 2
Retinal Abnormalities
Ultrawide fundus photography is conducted OU to assess retinal abnormalities
Time frame: Baseline through Year 2
Adverse Events (AEs)
Frequency of ocular adverse events (AEs)
Time frame: Screening through Year 2
Genomic Analysis for Study Eligibility
OPA1 genetic testing at screening visit
Time frame: Screening
Vital signs
Vital signs assessments (pulse rate, body temperature, systolic and diastolic blood pressure, and respiratory rate) performed in participants undergoing the DARC assessment only.
Time frame: Baseline through Year 2
To determine the outcome measures that are associated with ADOA disease progression.
To understand the disease progression in participants with confirmed OPA1 mutation-associated ADOA determined by changes in structural and functional markers from the primary outcome within the study period.
Time frame: Baseline through Year 2
To evaluate the safety of ANX776 in patients ≥ 12 years.
Incidence, type and severity of treatment-emergent and treatment-related AEs in patients ≥ 12 years. Changes from baseline in vital signs (pulse rate, body temperature, systolic and diastolic blood pressure, and respiration rate) in patients ≥ 12 years.
Time frame: Baseline through Year 2
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2024 to primary completion in Mar 2025, 12 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Optic Atrophy, Autosomal Dominant
PYC Therapeutics